141 Spam-Free Article(s) Found
Article Searches
What's in the Cards for Merrimack (MACK) in Q1 Earnings? http://www.zacks.com/stock/news/302167/whats-in-the-cards-for-merrimack-mack-in-q1-earnings?cid=CS-ZC-FT-302167 May 03, 2018 - Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.
Arris trims losses though revenue falls short in Q1 https://seekingalpha.com/news/3351163-arris-trims-losses-though-revenue-falls-short-q1?source=feed_news_all May 01, 2018 - Arris Group (NASDAQ:ARRS) turned in a mixed report in Q1 earnings, substantially trimming its net loss but seeing revenues fall short of expectations. Net loss on a GAAP basis was $0.07/share, vs. a
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond https://seekingalpha.com/article/4167853-jfs-core-biotech-buys-13-continued-market-headwinds-respond?source=feed_all_articles May 01, 2018 - The thesis for position #18, Ionis Pharmaceuticals, has been added.Weakness in the overall market and biotech sector continues to frustrate (and scare) many investors.I remind readers that I am not a
Game Plan For The Week - Cramer's Mad Money (4/27/18) https://seekingalpha.com/article/4167459-game-plan-week-cramers-mad-money-4-27-18?source=feed_tag_cramers_picks Apr 30, 2018 - Apple will have a weak quarter.Wal-Mart and Apple will be the biggest losers from a trade war with China.Chegg is a consistent company.
Jim Cramer Advises His Viewers On Array Biopharma, Chegg And PPG Industries http://feeds.benzinga.com/~r/benzinga/~3/VK-ltxnRtys/jim-cramer-advises-his-viewers-on-array-biopharma-chegg-and-ppg-industries Apr 30, 2018 -

On CNBC's "Mad Money", Jim Cramer advised his viewer to be careful with Array Biopharma Inc (NASDAQ: ARRY) because the market is taking apart the minor drug companies.

read more

JF's Core Biotech Buys #12: Updates And Introducing Our 18th Selection https://seekingalpha.com/article/4165041-jfs-core-biotech-buys-12-updates-introducing-18th-selection?source=feed Apr 24, 2018 - President Trump´s speech on drug pricing has been postponed. Continued deal activity in the biotech sector bodes well. Abeona Therapeutics announced receipt of the FDA´s RMAT (Regenerative Medicine Ad
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position https://seekingalpha.com/article/4163485-jfs-core-biotech-buys-11-positive-news-several-holdings-change-benchmarks-introducing-17th?source=feed_all_articles Apr 17, 2018 - Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.I explain below why I´ve made the choice to use dual benchmarks instead o
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position https://seekingalpha.com/article/4161978-jfs-core-biotech-buys-10-incyte-disappoints-optimism-returns-gene-therapy-new-position?source=feed Apr 10, 2018 - The rollercoaster ride in the gene therapy space (pessimism due to clinical hold/safety fears followed by optimism over Novartis acquiring AveXis) has been an interesting case study to watch. We took
By The Numbers: Best Biotech Stocks https://seekingalpha.com/article/4161156-numbers-best-biotech-stocks?source=feed Apr 05, 2018 - The biotech sector is fertile ground for tremendously profitable stocks, but many of the names in the sector are also quite risky and volatile.Since the dispersion in returns is so wide in biotech, pi
JF's Core Biotech Buys #9: Shire In Play, Volatility Continues And Capitalizing On Weakness https://seekingalpha.com/article/4160795-jfs-core-biotech-buys-9-shire-play-volatility-continues-capitalizing-weakness?source=feed_all_articles Apr 03, 2018 - The biotech sector (and overall market) continue to experience significant weakness.If Takeda successfully bids for Shire (or rival biders come in) it could provide a much-needed boost for the biotech

Pages: 12345678...15

<<<Page 3>